John D. Zehren
Directeur/Membre du Conseil chez Singlepass, Inc.
Profil
John D.
Zehren is an Independent Director at Singlepass, Inc. since 2022.
Previously, he was the Chief Commercial Officer at Endologix LLC from 2019 to 2020.
He completed his undergraduate degree at the University of St. Thomas.
Postes actifs de John D. Zehren
| Sociétés | Poste | Début |
|---|---|---|
Singlepass, Inc.
 Singlepass, Inc. Medical SpecialtiesHealth Technology Singlepass, Inc. has developed a unique electrocautery device that improves the clinical outcomes of deep tissue biopsy procedures. The company is based in Lake Forest, CA. The patented, single-use device prevents and stops bleeding caused by tissue extraction by cauterizing the tissue channel. It is the only cautery device of its kind that can be used for biopsy procedures. Singlepass was founded by Peter Sunenshine and Kevin Hirsch. The CEO is Bill Colone. | Directeur/Membre du Conseil | 18/03/2022 |
Anciens postes connus de John D. Zehren
| Sociétés | Poste | Fin |
|---|---|---|
| ENDOLOGIX, INC. | Corporate Officer/Principal | 14/04/2020 |
Formation de John D. Zehren
| University of St. Thomas | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Endologix LLC
 Endologix LLC Medical SpecialtiesHealth Technology Endologix LLC engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, Nellix and Ovation. The company was founded in March 1992 and is headquartered in Irvine, CA. | Health Technology |
Singlepass, Inc.
Singlepass, Inc. Medical SpecialtiesHealth Technology Singlepass, Inc. has developed a unique electrocautery device that improves the clinical outcomes of deep tissue biopsy procedures. The company is based in Lake Forest, CA. The patented, single-use device prevents and stops bleeding caused by tissue extraction by cauterizing the tissue channel. It is the only cautery device of its kind that can be used for biopsy procedures. Singlepass was founded by Peter Sunenshine and Kevin Hirsch. The CEO is Bill Colone. | Health Technology |
